99 related articles for article (PubMed ID: 23252250)
1. [Long-term entecavir efficacy retention in the treatment of chronic hepatitis B with an outcome to hepatic cirrhosis caused by its resistant virus strain].
Znoiko OO; Dudina KR; Safiullina NKh; Karandashova IV; Chulanov VP
Ter Arkh; 2012; 84(11):61-3. PubMed ID: 23252250
[TBL] [Abstract][Full Text] [Related]
2. [Antiviral effects of entecavir in patients with hepatitis B virus-related cirrhosis].
Xu Y; Wang JB; Xu J; Jiao J; Zhang YG; Ji SW; Zhao P; Guo HH; Li Y; Zhou CY
Zhonghua Gan Zang Bing Za Zhi; 2010 Feb; 18(2):109-12. PubMed ID: 20196949
[TBL] [Abstract][Full Text] [Related]
3. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis.
Wong GL; Chan HL; Mak CW; Lee SK; Ip ZM; Lam AT; Iu HW; Leung JM; Lai JW; Lo AO; Chan HY; Wong VW
Hepatology; 2013 Nov; 58(5):1537-47. PubMed ID: 23389810
[TBL] [Abstract][Full Text] [Related]
4. Economic analysis between entecavir and lamivudine for the treatment of chronic hepatitis B in Hong Kong.
Lee KK; Wu DB; Chow PY; Lee VW; Li H
J Gastroenterol Hepatol; 2012 Jul; 27(7):1167-74. PubMed ID: 22141402
[TBL] [Abstract][Full Text] [Related]
5. Entecavir: a potent antiviral with minimal long-term resistance in nucleoside-naive chronic hepatitis B patients.
Cheng PN; Chang TT
Expert Rev Anti Infect Ther; 2008 Oct; 6(5):569-79. PubMed ID: 18847396
[TBL] [Abstract][Full Text] [Related]
6. [Entecavir therapy against hepatitis B].
Kato N; Omata M
Nihon Rinsho; 2004 Aug; 62 Suppl 8():340-4. PubMed ID: 15453342
[No Abstract] [Full Text] [Related]
7. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation.
Fung J; Cheung C; Chan SC; Yuen MF; Chok KS; Sharr W; Dai WC; Chan AC; Cheung TT; Tsang S; Lam B; Lai CL; Lo CM
Gastroenterology; 2011 Oct; 141(4):1212-9. PubMed ID: 21762659
[TBL] [Abstract][Full Text] [Related]
8. Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety.
Yuen MF; Seto WK; Fung J; Wong DK; Yuen JC; Lai CL
Am J Gastroenterol; 2011 Jul; 106(7):1264-71. PubMed ID: 21364549
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis.
Schiff E; Simsek H; Lee WM; Chao YC; Sette H; Janssen HL; Han SH; Goodman Z; Yang J; Brett-Smith H; Tamez R
Am J Gastroenterol; 2008 Nov; 103(11):2776-83. PubMed ID: 18721244
[TBL] [Abstract][Full Text] [Related]
10. Entecavir for the treatment of chronic hepatitis B virus infection.
Matthews SJ
Clin Ther; 2006 Feb; 28(2):184-203. PubMed ID: 16678641
[TBL] [Abstract][Full Text] [Related]
11. Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: successful rescue therapy with tenofovir.
Leemans WF; Niesters HG; van der Eijk AA; Janssen HL; Schalm SW; de Man RA
Eur J Gastroenterol Hepatol; 2008 Aug; 20(8):773-7. PubMed ID: 18617782
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of entecavir in clinical practice in treatment-naive Caucasian chronic hepatitis B patients.
Buti M; Morillas RM; Prieto M; Diago M; Pérez J; Solà R; Bonet L; Palau A; Testillano M; García-Samaniego J; Rodríguez M;
Eur J Gastroenterol Hepatol; 2012 May; 24(5):535-42. PubMed ID: 22382708
[TBL] [Abstract][Full Text] [Related]
13. Entecavir in decompensated HBV cirrhosis: the future is looking brighter.
Fontana RJ
J Hepatol; 2010 Feb; 52(2):147-9. PubMed ID: 20006400
[No Abstract] [Full Text] [Related]
14. Entecavir versus lamivudine in the treatment of chronic hepatitis B patients with hepatic decompensation.
Hsu YC; Mo LR; Chang CY; Perng DS; Tseng CH; Lo GH; Tai CM; Lin CW; Hsu CC; Hsu CY; Huang SC; Lin JT
Antivir Ther; 2012; 17(4):605-12. PubMed ID: 22301517
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients.
Suzuki F; Toyoda J; Katano Y; Sata M; Moriyama M; Imazeki F; Kage M; Seriu T; Omata M; Kumada H
J Gastroenterol Hepatol; 2008 Sep; 23(9):1320-6. PubMed ID: 18554238
[TBL] [Abstract][Full Text] [Related]
16. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.
Lai CL; Shouval D; Lok AS; Chang TT; Cheinquer H; Goodman Z; DeHertogh D; Wilber R; Zink RC; Cross A; Colonno R; Fernandes L;
N Engl J Med; 2006 Mar; 354(10):1011-20. PubMed ID: 16525138
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis B virus resistance to entecavir in nucleoside naïve patients: Does it exist?
Zoulim F
Hepatology; 2006 Dec; 44(6):1404-7. PubMed ID: 17133478
[No Abstract] [Full Text] [Related]
18. [Results of 3 years of continuous entecavir treatment in nucleos(t)ide-naive chronic hepatitis B patients].
Yao GB; Ren H; Xu DZ; Zhou XQ; Jia JD; Wang YM; Chen CW
Zhonghua Gan Zang Bing Za Zhi; 2009 Dec; 17(12):881-6. PubMed ID: 20038326
[TBL] [Abstract][Full Text] [Related]
19. [Chronic HBeAg-negative viral gepatitis B: treatment is essential and possible].
Isakov VA
Eksp Klin Gastroenterol; 2007; (5):40-5. PubMed ID: 18389596
[No Abstract] [Full Text] [Related]
20. Entecavir: a new nucleoside analog for the treatment of chronic hepatitis B infection.
Sims KA; Woodland AM
Pharmacotherapy; 2006 Dec; 26(12):1745-57. PubMed ID: 17125436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
